Humanised SARS-CoV-2 Antibodies
The Native Antigen Company now offers humanised, recombinant versions of its monoclonal anti-SARS-CoV-2 Spike antibodies. These antibodies have been tested against our range of Spike variants, showing differential binding affinities.
Humanised Antibodies
Humanised antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to human antibodies. When designing assays to qualify and quantify patient sera, humanised antibodies can therefore act as “truer” patient controls than their monoclonal equivalents from mice or rabbits. When developing human therapeutics, humanised antibodies are similarly needed due to the induction of off-target immune responses against antibodies from animal species.
Our Expanded Range
The Native Antigen Company offers five humanised, recombinant versions of its monoclonal Spike-specific SARS-CoV-2 antibodies. These antibodies have been tested against Spike proteins from a range of variants, showing differential binding affinities and neutralising ability:
(Wild Type)
(Alpha)
(Beta)
(Gamma)
(Kerala)
(Delta)
(Omicron)
(Non-RBD)
(Non-RBD)
(Non-RBD)
(Non-RBD)
(Non-RBD)
(Non-RBD)
(Non-RBD)
(Non-RBD)
(Non-RBD)
(Non-RBD)
(Non-RBD)
(Non-RBD)
For more information on these antibodies, click the buttons below or get in touch with a member of our team:
See our Full Range
The Native Antigen Company provides an extensive range of reagents to support coronavirus R&D, including antigens, antibodies, receptors, enzymes, neutralisation kits and contract services.